Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson disease

Annals of Neurology

Volumn 40, Issue 3, 1996, Pages 463-465

  Diederich, Nico ^a,e   Hilger, Christiane ^a   Goetz, Christopher G ^d   Keipes, Marc ^b   Hentges, François ^a   Vieregge, Peter ^c   Metz, Henri ^a  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b Clinic St Therese   (Luxembourg)

^c Neurologische Univ Klin   (Germany)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Luxembourg Medical Center   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; OXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029835547     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400319     Document Type: Article

References (15)

1. Barbeau A, Roy M, Paris S. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2:1213-1215
2. Kallio J, Marttila RJ, Rinne UK, et al. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991;83:194-197
3. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P-450 CYP 2D6 locus. Nature 1990;347:773-776
4. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Patkinson's disease. Lancet 1992;339:1375-1377
5. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339:1017-1018
6. Bordet R, Broly F, Destée A, et al. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Adv Neurol 1996;69:97-100
7. Kurth JH, Hubble JP, Eggers EA, et al. Lack of association of CYP 2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort. Neurology 1995;45(suppl 4):A429 (Abstract)
8. Planté-Bordeneuve V, Davis MB, Maraganore DM, et al. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:911-913
9. Kidd KK. An overview of DNA variation in the human species. Abstract 312, presented at the 8th International Congress Human Genetics, 1991
10. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 2:529-532
11. Ayesh R, Idle JR, Ritchie JC, et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312:169-170
12. Johnson WG. Genetic susceptibility to Parkinson's disease. Neurology 1991;41(suppl 2):82-87
13. Moller H, Mellemkjaer L, Mc Laughin JK, et al. Occurrence of different cancers in patients with Parkinson's disease. Br Med J 1995;310:1500-1501
14. Tsuneoka Y, Matsuo Y, Iwahashi K, et al. A novel cytochome P-450 2D6 mutant gene associated with Parkinson's disease. J Biochem 1993;114:263-266
15. Chan P, Tanner CM, Langston JW. A new CYP 2D6 mutation associated with Parkinson's disease in American Caucasians. Mov Disord 1995;10:689 (Abstract)